Get the Stockscreener App
6.78
0.30%
0.02
After Hours:
6.78
Omeros Corporation stock is traded at $6.78, with a volume of 423.36K.
It is up +0.30% in the last 24 hours and down -20.42% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$6.76
Open:
$6.79
24h Volume:
423.36K
Relative Volume:
0.71
Market Cap:
$405.87M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-3.6064
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
+15.70%
1M Performance:
-20.42%
6M Performance:
+63.77%
1Y Performance:
+102.99%
1-Day Range:
$6.561
$6.875
1-Week Range:
$5.802
$7.19
52-Week Range:
$2.965
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
6.78 | 405.87M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Omeros Co. (NASDAQ:OMER) Shares Sold by ExodusPoint Capital Management LP - The AM Reporter
Vanguard Group Inc. Reduces Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Raymond James Financial Inc. Invests $124,000 in Omeros Co. (NASDAQ:OMER) - Defense World
D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Corebridge Financial Inc. Sells 2,100 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros' New Leukemia Drug Team Ignites Hope For Cancer FightOmeros (NASDAQ:OMER) - Benzinga
Omeros Announces the Omeros Oncology Clinical Steering Committee - GuruFocus
Omeros forms steering committee for leukemia treatment By Investing.com - Investing.com South Africa
Omeros announces oncology clinical steering committee to help guide proprietary Oncotox-AML clinical program - marketscreener.com
Omeros forms steering committee for leukemia treatment - Investing.com
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program - The Joplin Globe
MD Anderson Expert Leads Omeros' Revolutionary AML Drug DevelopmentTargets 90% of Patients - Stock Titan
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell - Defense World
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases - Yahoo Finance
Revolutionary T-CAT Platform Takes Aim at $135B Antibiotic Crisis with 99% Kill Rate - Stock Titan
It makes sense and dollars to buy Omeros Corporation (OMER) stock - Sete News
(OMER) Technical Data - news.stocktradersdaily.com
FY2025 EPS Estimates for Omeros Reduced by Cantor Fitzgerald - Defense World
Omeros (NASDAQ:OMER) Upgraded to Hold at StockNews.com - The AM Reporter
Omeros (NASDAQ:OMER) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Omeros Co. (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
4,671 Shares in Omeros Co. (NASDAQ:OMER) Acquired by Quantbot Technologies LP - Defense World
Omeros (NASDAQ:OMER) Receives “Hold” Rating from Needham & Company LLC - Defense World
Omeros (NASDAQ:OMER) Receives “Buy” Rating from D. Boral Capital - Defense World
Omeros Corporation’s Earnings Call Highlights Progress and Challenges - TipRanks
Omeros Corporation (NASDAQ:OMER) Q4 2024 Earnings Call Transcript - Insider Monkey
Omeros (OMER) Exceeds Q4 EPS Expectations, Reports Cash Decline - GuruFocus
Omeros: Q4 Earnings Snapshot - CT Insider
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with Strategic Initiatives - GuruFocus
Omeros Corporation Reports 2024 Financial Results - TipRanks
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs - Investing.com Canada
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs By Investing.com - Investing.com South Africa
Omeros beats Q4 earnings estimates, shares rise 5% By Investing.com - Investing.com South Africa
Omeros beats Q4 earnings estimates, shares rise 5% - Investing.com Australia
OMEROS CORP SEC 10-K Report - TradingView
Omeros reports Q4 EPS (54c), consensus (71c) - TipRanks
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results - Yahoo Finance
Omeros (OMER) to Release Quarterly Earnings on Monday - Defense World
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Benzinga
In the Green: Omeros Corporation (OMER) Closes at 8.52, Up/Down -6.99 from Previous Day - DWinneX
Omeros Corporation (OMER) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Trend Tracker for (OMER) - news.stocktradersdaily.com
Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements - TipRanks
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 - Joplin Globe
Omeros Earnings Preview: Key Metrics to Watch in Q4 and Full Year Report - Stock Titan
Charles Schwab Investment Management Inc. Decreases Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Bank of New York Mellon Corp Sells 4,919 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros to activate site for Phase III programme of zaltenibart for PNH - Yahoo Finance
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):